November 27, 2017 05:34 AM EST

With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback

Just a few weeks after Novartis $NVS spelled out exactly why it believes RTH258 can carve out a blockbuster chunk of Regeneron’s AMD market …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With No­var­tis clos­ing in, Re­gen­eron scraps Eylea com­bo drug in a ma­jor set­back